The Biotech Brief Podcast Por The HEII arte de portada

The Biotech Brief

The Biotech Brief

De: The HEII
Escúchala gratis

We quickly breakdown the latest news in biotech. Fast Facts. Big Breakthroughs.Copyright 2025 All rights reserved. Ciencia Ciencias Biológicas
Episodios
  • 6: From Approval to Access

    6: From Approval to Access
    Jul 11 2025

    Gilead’s twice-yearly injectable PrEP, Yeztugo was recently approved by the FDA, but the story doesn’t end there. In this episode of The Biotech Brief, we explore how Gilead is leveraging global partnerships, generics, and regulatory streamlining to deliver Yeztugo to low- and middle-income countries without delay. Building on Episode 1, “Changing the Game in HIV Prevention,” this follow-up digs into what equitable access really takes and what drug developers can learn from it.
    Más Menos
    5 m
  • 5: Street Pricing, Corporate Cartels, and the Generic Drug Price War

    5: Street Pricing, Corporate Cartels, and the Generic Drug Price War
    Jul 9 2025

    Southwest Airlines is taking generic drugmakers to court and accusing more than 20 companies of price fixing that inflated costs for millions of Americans, including its own employees. In this episode of The Biotech Brief, we unpack the lawsuit, the history of generic drug cartel behavior, and why drug developers (yes, even biotech innovators) should be paying close attention. This episode explores how drug pricing moves from boardroom strategy to national scandal.
    Más Menos
    6 m
  • 4: Rebranding Vision

    4: Rebranding Vision
    Jul 8 2025

    Ocular Therapeutix is rebranding and repositioning. This episode of The Biotech Brief breaks down their plans for competing in the Wet AMD space, the company’s brand pivot to be more retina focused, and why this branding shift is more strategic than cosmetic.
    Más Menos
    4 m
Todavía no hay opiniones